Coverage Limitations for Use of Urine Drug Testing in a State Medicaid Program
-
By
-
Michael A. Incze
-
Sarah R. Tingley
-
John Neuhaus
-
Marcus Bachhuber
-
S. Amanda Dumas
-
Sanket S. Dhruva
-
Rita F. Redberg
-
May 8, 2026
-
Clinical Scorecard: Limitations in Medicaid Coverage for Urine Drug Testing Utilization
At a Glance
| Category | Detail |
|---|
| Condition | Substance Use Disorders (SUDs) |
| Key Mechanisms | Urine drug testing (UDT) for assessing substance use and medication adherence. |
| Target Population | Louisiana Medicaid beneficiaries aged 16 to 64 years. |
| Care Setting | Medicaid fee-for-service and managed care. |
Key Highlights
- Opioid overdose accounted for an estimated 3.1 million years of life lost in 2022.
- Fewer than 25% of individuals with SUDs receive treatment.
- Louisiana Medicaid policy limits UDT reimbursement to 24 presumptive and 18 definitive tests per year.
Guideline-Based Recommendations
Diagnosis
- Utilize UDT to assess for unreported substance use in SUD treatment.
Management
- Implement evidence-based training and policies for UDT use.
Monitoring & Follow-up
- Track UDT utilization and associated health outcomes post-policy enactment.
Risks
- Potential for low-value care due to high spending on UDT with uncertain benefits.
Patient & Prescribing Data
Louisiana Medicaid beneficiaries aged 16 to 64 years.
Monitoring of UDT utilization trends and associated SUD treatment outcomes.
Clinical Best Practices
- Adopt standardized UDT policies to reduce variability in testing practices.
- Avoid stigmatization of patients based on UDT results.
References
